JP2019512272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512272A5 JP2019512272A5 JP2019500742A JP2019500742A JP2019512272A5 JP 2019512272 A5 JP2019512272 A5 JP 2019512272A5 JP 2019500742 A JP2019500742 A JP 2019500742A JP 2019500742 A JP2019500742 A JP 2019500742A JP 2019512272 A5 JP2019512272 A5 JP 2019512272A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor targeting
- molecule
- targeting moiety
- item
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022062657A JP2022088627A (ja) | 2016-03-21 | 2022-04-04 | 多重特異性および多機能性分子ならびにその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310899P | 2016-03-21 | 2016-03-21 | |
| US201662310929P | 2016-03-21 | 2016-03-21 | |
| US62/310,929 | 2016-03-21 | ||
| US62/310,899 | 2016-03-21 | ||
| PCT/US2017/023483 WO2017165464A1 (en) | 2016-03-21 | 2017-03-21 | Multispecific and multifunctional molecules and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022062657A Division JP2022088627A (ja) | 2016-03-21 | 2022-04-04 | 多重特異性および多機能性分子ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512272A JP2019512272A (ja) | 2019-05-16 |
| JP2019512272A5 true JP2019512272A5 (enExample) | 2020-04-30 |
| JP7082604B2 JP7082604B2 (ja) | 2022-06-08 |
Family
ID=58578974
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500742A Active JP7082604B2 (ja) | 2016-03-21 | 2017-03-21 | 多重特異性および多機能性分子ならびにその使用 |
| JP2022062657A Pending JP2022088627A (ja) | 2016-03-21 | 2022-04-04 | 多重特異性および多機能性分子ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022062657A Pending JP2022088627A (ja) | 2016-03-21 | 2022-04-04 | 多重特異性および多機能性分子ならびにその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11291721B2 (enExample) |
| EP (1) | EP3433281A1 (enExample) |
| JP (2) | JP7082604B2 (enExample) |
| CN (1) | CN109153728A (enExample) |
| AU (1) | AU2017238172B2 (enExample) |
| CA (1) | CA3016563A1 (enExample) |
| WO (1) | WO2017165464A1 (enExample) |
Families Citing this family (171)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
| CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
| EP3233920B1 (en) | 2014-12-19 | 2020-08-26 | Alkermes, Inc. | Single chain fc fusion proteins |
| JP7461620B2 (ja) | 2015-10-06 | 2024-04-04 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 治療用化合物及び方法 |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| WO2017136837A1 (en) | 2016-02-06 | 2017-08-10 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| MA45554A (fr) | 2016-07-01 | 2019-05-08 | Resolve Therapeutics Llc | Fusions de binucléase optimisées. |
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| AU2017295704B2 (en) | 2016-07-13 | 2023-07-13 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
| CN110418651A (zh) | 2016-08-02 | 2019-11-05 | 哈佛学院院长等 | 用于调节免疫应答的生物材料 |
| CA3036564A1 (en) * | 2016-09-23 | 2018-03-29 | Elstar Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
| CA3052463A1 (en) | 2017-02-03 | 2018-08-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
| AU2018220734B2 (en) * | 2017-02-20 | 2025-03-06 | Dragonfly Therapeutics, Inc. | Proteins binding CD33, NKG2D and CD16 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| WO2018178076A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| EP3612563A1 (en) | 2017-04-19 | 2020-02-26 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| EP4328241A3 (en) * | 2017-04-28 | 2024-06-05 | Marengo Therapeutics, Inc. | Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof |
| JP2020528878A (ja) * | 2017-06-20 | 2020-10-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | がん治療用インターフェロンプロドラッグ |
| MX2020001309A (es) | 2017-08-02 | 2020-08-20 | Phanes Therapeutics Inc | Anticuerpos anti-cd47 y sus usos. |
| CN118126157A (zh) | 2017-08-03 | 2024-06-04 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
| CN111315767B (zh) | 2017-08-22 | 2025-03-18 | 萨纳生物有限责任公司 | 可溶性干扰素受体及其用途 |
| JP7795181B2 (ja) | 2017-09-06 | 2026-01-07 | イェール ユニバーシティー | インターロイキン－１８バリアントとその利用法 |
| US11883503B2 (en) * | 2017-09-25 | 2024-01-30 | Dingfu Biotarget Co., Ltd. | Methods and compositions for cancer treatment |
| WO2019089755A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| EP3704155A2 (en) * | 2017-11-01 | 2020-09-09 | F. Hoffmann-La Roche AG | Combination therapy with targeted ox40 agonists |
| CN107903324B (zh) * | 2017-11-15 | 2021-01-29 | 北京绿竹生物技术股份有限公司 | 一种结合人cd19和cd3的双特异性抗体 |
| JP7348899B2 (ja) * | 2017-12-08 | 2023-09-21 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性分子及びその使用 |
| US11795226B2 (en) | 2017-12-12 | 2023-10-24 | Macrogenics, Inc. | Bispecific CD16-binding molecules and their use in the treatment of disease |
| CN111448217A (zh) | 2017-12-22 | 2020-07-24 | 阿根思公司 | 双特异性抗原结合构建体 |
| US11970537B2 (en) | 2017-12-26 | 2024-04-30 | Nanjing GenScript Biotech Co., Ltd. | Fusion protein dimer using antibody Fc region as backbone and use thereof |
| US12036273B2 (en) | 2018-01-08 | 2024-07-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods for targeting CD99-expressing cancers |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| MX2020007291A (es) | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
| CA3090406A1 (en) * | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| CN108383911A (zh) * | 2018-02-06 | 2018-08-10 | 广州市拜沃思生物科技有限公司 | 一种双特异性抗体及其制备方法和应用 |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CN112119093A (zh) * | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| WO2019166650A1 (en) * | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
| SG11202008568WA (en) | 2018-03-09 | 2020-10-29 | Sorrento Therapeutics Inc | Dimeric antigen receptors (dar) |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3765516A2 (en) * | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| KR20260100427A (ko) * | 2018-03-28 | 2026-06-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 이작용성 단백질 및 이의 작제물 |
| KR20200142525A (ko) * | 2018-04-05 | 2020-12-22 | 노파르티스 아게 | 암에 대한 삼중특이성 결합 분자 및 이의 용도 |
| SG11202011139YA (en) * | 2018-05-16 | 2020-12-30 | Dragonfly Therapeutics Inc | Protein binding nkg2d, cd16 and a fibroblast activation protein |
| CN112384534A (zh) * | 2018-05-21 | 2021-02-19 | 指南针制药有限责任公司 | 用于增强nk细胞对靶细胞的杀死的组合物和方法 |
| WO2019226658A1 (en) * | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
| CN109536476A (zh) * | 2018-05-21 | 2019-03-29 | 沣潮医药科技（上海）有限公司 | 具备透明质酸酶活性的靶向融合蛋白、制备方法及用途 |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| PE20210320A1 (es) | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CA3108427A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) * | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020033702A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| US11066476B2 (en) * | 2018-09-14 | 2021-07-20 | Shanghai tongji hospital | Asymmetric bispecific antibody |
| WO2020061129A1 (en) | 2018-09-19 | 2020-03-26 | President And Fellows Of Harvard College | Compositions and methods for labeling and modulation of cells in vitro and in vivo |
| JP7465272B2 (ja) | 2018-09-27 | 2024-04-10 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体 |
| US11242396B2 (en) * | 2018-10-01 | 2022-02-08 | Hoffmann-La Roche Inc. | Bispecific antigen binding molecules comprising anti-FAP clone 212 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP7728701B2 (ja) * | 2018-12-17 | 2025-08-25 | レビトープ リミテッド | 双子型免疫細胞エンゲージャー |
| JP2022514568A (ja) | 2018-12-17 | 2022-02-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫系のモジュレーションのための生物工学的スキャフォールドおよびその使用 |
| CN111378044B (zh) * | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
| CN111378045B (zh) * | 2018-12-28 | 2022-08-02 | 长春金赛药业有限责任公司 | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 |
| AU2020226893B2 (en) * | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| WO2020172598A1 (en) * | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| JP7579795B2 (ja) * | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| SG11202109056TA (en) * | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020177627A1 (zh) * | 2019-03-02 | 2020-09-10 | 上海一宸医药科技有限公司 | 一种双特异抗体 |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2020193718A1 (en) * | 2019-03-27 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| WO2020198665A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| CN113840833B (zh) * | 2019-03-28 | 2025-06-17 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| EP3959237A1 (en) * | 2019-04-25 | 2022-03-02 | F. Hoffmann-La Roche AG | Therapeutic multispecific polypeptides activated by polypeptide chain exchange |
| JP2022532249A (ja) * | 2019-05-16 | 2022-07-13 | アーチ オンコロジー，インコーポレイテッド | インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法 |
| AU2020279224B2 (en) | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| CN114174325A (zh) * | 2019-06-04 | 2022-03-11 | 恩卡尔塔公司 | 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合 |
| CN110256583B (zh) * | 2019-07-11 | 2022-05-20 | 中国科学院生物物理研究所 | 一种il-2突变体与抗体的融合蛋白及其应用 |
| CN120842421A (zh) * | 2019-07-30 | 2025-10-28 | 魁尔斯弗生物治疗股份有限公司 | 双特异性抗LRRC15和CD3ε抗体 |
| MX2022001942A (es) * | 2019-08-15 | 2022-07-27 | Regeneron Pharma | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. |
| BR112022004712A2 (pt) * | 2019-09-16 | 2022-06-14 | Gt Biopharma Inc | Compostos e métodos de imunoterapia |
| JP2022549270A (ja) | 2019-09-23 | 2022-11-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | バイオマテリアルベースの無抗原ワクチンおよびその使用 |
| TWI878355B (zh) * | 2019-10-02 | 2025-04-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
| US20220362163A1 (en) * | 2019-10-18 | 2022-11-17 | The University Of North Carolina At Chapel Hill | Methods and compositions for cancer treatment using nanoparticles conjugated with multiple ligands for binding receptors on nk cells |
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| EP4084821A4 (en) * | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2021155151A1 (en) * | 2020-01-29 | 2021-08-05 | The Methodist Hospital System | Multivalent ligands targeting cell surface receptors and force measurement platform for making the same |
| US12486331B2 (en) | 2020-01-31 | 2025-12-02 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| EP4110820A4 (en) * | 2020-02-25 | 2024-03-27 | Gensun Biopharma Inc. | Trispecific t cell engagers |
| CN113461824A (zh) * | 2020-03-31 | 2021-10-01 | 普米斯生物技术(珠海)有限公司 | 一种构建多特异性抗体的平台 |
| US20230151115A1 (en) * | 2020-03-31 | 2023-05-18 | University Public Corporation Osaka | Multispecific antibody and method for producing same |
| WO2021205027A1 (en) | 2020-04-09 | 2021-10-14 | Vaccibody As | Individualized therapeutic anticancer vaccine |
| AU2021261420A1 (en) * | 2020-04-24 | 2022-12-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| CN115996952A (zh) * | 2020-06-11 | 2023-04-21 | 提圣纳医疗公司 | 对hla-g和另一种抗原具有结合特异性的双特异性免疫细胞接合子 |
| US12594341B2 (en) | 2020-06-14 | 2026-04-07 | Shimon Slavin | Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates |
| KR20220014531A (ko) * | 2020-07-29 | 2022-02-07 | (주)메디톡스 | 헤테로이량체 Ｆｃ 융합 단백질, 및 관련 조성물, 용도 및 방법 |
| CA3187850A1 (en) | 2020-08-04 | 2022-02-10 | Bryan Glaser | Pd-l1 binding agents and uses thereof |
| KR102799318B1 (ko) * | 2020-08-11 | 2025-04-23 | 주식회사 카나프테라퓨틱스 | Il-12 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도 |
| US20230416364A1 (en) * | 2020-08-13 | 2023-12-28 | Bristol-Myers Squibb Company | Methods of redirecting of il-2 to target cells of interest |
| JP2023539645A (ja) * | 2020-08-26 | 2023-09-15 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｎｋｐ３０に結合する抗体分子およびその使用 |
| CA3190573A1 (en) * | 2020-08-26 | 2022-03-03 | Andreas Loew | Methods of detecting trbc1 or trbc2 |
| AU2021331075A1 (en) * | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2022049061A1 (en) * | 2020-09-01 | 2022-03-10 | Merck Patent Gmbh | Nkp30 binders |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| WO2022099093A1 (en) * | 2020-11-06 | 2022-05-12 | President And Fellows Of Harvard College | Scaffolds for enhancing neutrophils and uses thereof |
| JP2023552289A (ja) | 2020-11-19 | 2023-12-15 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法 |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| US20250270320A1 (en) | 2020-12-10 | 2025-08-28 | Eutilex Co., Ltd. | Anti-pd-1 antibody and uses thereof |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| CN114716548B (zh) | 2021-01-05 | 2024-11-05 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
| US20250074996A1 (en) * | 2021-02-19 | 2025-03-06 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| JP2024513313A (ja) | 2021-03-08 | 2024-03-25 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | ＣＤ６６ｅポリペプチドに結合する分子 |
| WO2022190016A1 (en) * | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| CN117321087A (zh) * | 2021-03-26 | 2023-12-29 | 先天制药公司 | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 |
| CA3214757A1 (en) * | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| KR20230169182A (ko) * | 2021-04-09 | 2023-12-15 | 몰리큘라 파트너스 아게 | 신규한 DARPin 기반 CD70 인게이저 |
| EP4329786A4 (en) | 2021-04-30 | 2024-12-11 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| EP4341289A1 (en) * | 2021-05-18 | 2024-03-27 | Christian-Albrechts-Universität zu Kiel | Co-stimulatory multispecific antibodies |
| CN117616050A (zh) * | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
| KR20240019786A (ko) * | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체 |
| WO2022258678A1 (en) * | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) * | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| WO2022262678A1 (zh) * | 2021-06-15 | 2022-12-22 | 盛禾(中国)生物制药有限公司 | 一种多特异性抗原结合蛋白及其应用 |
| US20240327543A1 (en) * | 2021-08-02 | 2024-10-03 | Shenghe (China) Biopharmaceutical Co., Ltd. | Multispecific antigen-binding protein and use thereof |
| WO2023020315A1 (zh) * | 2021-08-19 | 2023-02-23 | 南京吉盛澳玛生物医药有限公司 | 靶向pd-l1/pd-1的抗体及其应用 |
| WO2023036270A1 (zh) * | 2021-09-09 | 2023-03-16 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| CN114032252B (zh) * | 2021-11-01 | 2022-04-22 | 武汉爱博泰克生物科技有限公司 | 一种重组状态人源mmp-7蛋白的表达方法及应用 |
| CN114262382B (zh) * | 2021-12-20 | 2023-09-19 | 上海恩凯细胞技术有限公司 | 双特异性抗体及其应用 |
| CN114249836A (zh) * | 2021-12-27 | 2022-03-29 | 上海鑫湾生物科技有限公司 | 双特异性t细胞衔接器、其重组溶瘤病毒及其用途 |
| CN116496403A (zh) * | 2022-01-19 | 2023-07-28 | 泽达生物医药有限公司 | 抗pdl1/igf1r双特异性抗体、其制备方法及用途 |
| CN119053342A (zh) * | 2022-01-21 | 2024-11-29 | 礼进生物医药控股有限公司 | 用于亲合力受体交联和免疫调节的多特异性抗体 |
| EP4475886A4 (en) * | 2022-02-09 | 2026-03-18 | Exelixis Inc | MULTI-SPECIFIC LIAISON AGENTS AND THEIR USES |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| US20260166144A1 (en) * | 2022-04-07 | 2026-06-18 | Carsgen Life Sciences Co., Ltd. | Chimeric polypeptide and use thereof |
| WO2023204290A1 (ja) * | 2022-04-21 | 2023-10-26 | 愛知県 | 多重特異性ナノ粒子 |
| WO2024005422A1 (ko) * | 2022-06-29 | 2024-01-04 | 고려대학교 산학협력단 | Nkp30 결합력이 향상된 b7-h6 변이체 |
| WO2024006538A1 (en) * | 2022-06-30 | 2024-01-04 | The Johns Hopkins University | Use of a conjugate of anti-cd47 antibody and toll-like receptor agonist |
| IL318546A (en) | 2022-07-26 | 2025-03-01 | Aimed Bio Inc | Anti-ROR1 antibody and its uses |
| CN116003627B (zh) * | 2022-09-16 | 2025-05-13 | 四川大学华西医院 | NKG2D-NKp46细胞接合器分子及其用途 |
| KR20250093374A (ko) * | 2022-10-24 | 2025-06-24 | 머크 샤프 앤드 돔 엘엘씨 | 인간 히알루로니다제 1 돌연변이체 |
| GB202301945D0 (en) | 2023-02-10 | 2023-03-29 | Mount Natalie | Novel immunoconjugates |
| EP4680281A2 (en) * | 2023-03-13 | 2026-01-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for hiv latency reversal |
| WO2024197709A1 (zh) * | 2023-03-30 | 2024-10-03 | 中国科学院深圳先进技术研究院 | 一种t细胞衔接器及其制备方法和应用 |
| TW202506726A (zh) * | 2023-04-07 | 2025-02-16 | 美商麥迪紐有限責任公司 | 雙特異性工程化抗體 |
| EP4737482A1 (en) | 2023-06-27 | 2026-05-06 | Atheon Bio, Inc. | Humanized anti-myct1 antibody and use thereof |
| CN117069856B (zh) * | 2023-08-08 | 2024-03-26 | 北京翊博生物集团有限公司 | 双特异性抗体及应用、组合物、激活和扩增t细胞的方法 |
| WO2025063790A1 (ko) | 2023-09-20 | 2025-03-27 | 주식회사 유씨아이테라퓨틱스 | 항-메소텔린 항체 및 이의 용도 |
| WO2025121861A1 (ko) | 2023-12-04 | 2025-06-12 | 아테온바이오 주식회사 | 신규 항-myct1 인간항체 및 이의 용도 |
| WO2025133340A1 (en) | 2023-12-21 | 2025-06-26 | Ludwig Institute For Cancer Research Ltd | Heterodimeric proteins comprising dimerization motifs and methods of using |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2025158376A1 (en) * | 2024-01-26 | 2025-07-31 | Janssen Biotech, Inc. | Materials and methods for designing, use and manufacture of improved biologic molecules |
| TW202602921A (zh) * | 2024-02-09 | 2026-01-16 | 大陸商上海岸邁生物科技有限公司 | 多功能ｎｋ細胞接合器 |
| US20250361320A1 (en) | 2024-02-27 | 2025-11-27 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
| WO2025201242A1 (en) * | 2024-03-25 | 2025-10-02 | Tavotek Biotherapeutics (Hong Kong) Limited | Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof |
| WO2025242835A1 (en) * | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025242836A1 (en) * | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| EP4744681A1 (en) * | 2024-08-16 | 2026-05-20 | Shanghai Bao Pharmaceuticals Co., Ltd. | COMPLEX TARGETING TARGET CELLS AND ITS USE |
| US20260144885A1 (en) | 2024-11-22 | 2026-05-28 | Bristol-Myers Squibb Company | Anti-lrrc15 antibodies and uses thereof |
| CN119684472B (zh) * | 2024-12-13 | 2026-02-17 | 北京干细胞与再生医学研究院 | 靶向CD33和mesothelin双靶点的嵌合抗原受体及其应用 |
Family Cites Families (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5731116A (en) | 1989-05-17 | 1998-03-24 | Dai Nippon Printing Co., Ltd. | Electrostatic information recording medium and electrostatic information recording and reproducing method |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116615A (en) * | 1989-01-27 | 1992-05-26 | Immunolytics, Inc. | Method for treating benign prostatic hypertrophy |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| JP3980657B2 (ja) | 1992-06-26 | 2007-09-26 | 生化学工業株式会社 | コンドロイチナーゼａｂｃ、その製造法及び医薬組成物 |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| WO2000060070A1 (en) | 1999-04-01 | 2000-10-12 | Innogenetics N.V. | A polypeptide structure for use as a scaffold |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| CA2416219C (en) * | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| IL137419A0 (en) * | 2000-07-20 | 2001-07-24 | Yissum Res Dev Co | Nk cells activating receptors and their therapeutic and diagnostic uses |
| WO2002070647A2 (en) * | 2001-03-05 | 2002-09-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses |
| AU2003209272A1 (en) | 2002-01-16 | 2003-09-02 | Zyomyx, Inc. | Engineered binding proteins |
| US7906118B2 (en) * | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| AU2003294930B2 (en) * | 2002-12-23 | 2008-12-04 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| ME01803B (me) | 2004-08-05 | 2010-12-31 | Genentech Inc | Humanizovani anti-cmet antagonisti |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| CA2580796C (en) | 2004-09-24 | 2013-03-26 | Amgen Inc. | Modified fc molecules having peptides inserted in internal loop regions |
| CN101072793B (zh) * | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
| US7431380B1 (en) | 2005-02-24 | 2008-10-07 | Theodore Allen Buresh | Louver kit |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| AU2006237329B2 (en) * | 2005-04-18 | 2012-04-12 | Novo Nordisk A/S | IL-21 variants |
| WO2007016130A2 (en) * | 2005-07-27 | 2007-02-08 | Lipid Sciences, Inc. | A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
| WO2007101949A2 (fr) * | 2006-03-08 | 2007-09-13 | Biomethodes | Variants de l'interferon- gamma humain (infgamma) |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| AU2007285763B2 (en) | 2006-08-18 | 2011-12-15 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| EP2388266B1 (en) * | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| EP2504360B1 (en) | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| CA3220104A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US20120201746A1 (en) | 2010-12-22 | 2012-08-09 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| JP2014511836A (ja) | 2011-03-25 | 2014-05-19 | グレンマーク ファーマシューティカルズ， エセ．アー． | ヘテロ二量体免疫グロブリン |
| WO2013002362A1 (ja) | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| ES2767135T3 (es) | 2011-10-19 | 2020-06-16 | Novimmune Sa | Métodos para purificar anticuerpos |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| KR101814370B1 (ko) | 2011-12-27 | 2018-01-12 | 재단법인 생물기술개발중심 | 경쇄-가교된 이중특이성 항체 |
| MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
| GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| EP3517548A1 (en) | 2012-03-13 | 2019-07-31 | NovImmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| SG10201704846VA (en) | 2012-03-14 | 2017-07-28 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| EP3553089A1 (en) | 2012-05-10 | 2019-10-16 | Bioatla, LLC | Multi-specific monoclonal antibodies |
| JP6351572B2 (ja) | 2012-05-10 | 2018-07-04 | ザイムワークス，インコーポレイテッド | Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物 |
| MX2014014162A (es) | 2012-05-24 | 2015-02-04 | Hoffmann La Roche | Anticuerpos multiespecificos. |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| CA2871386A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof |
| WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| CN104640561A (zh) | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| CA2879814A1 (en) | 2012-08-02 | 2014-02-06 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP2904093B1 (en) | 2012-10-03 | 2019-04-10 | Zymeworks Inc. | Methods of quantitating heavy and light chain polypeptide pairs |
| MX2015003616A (es) | 2012-10-08 | 2015-06-05 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso. |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| EP2934577A1 (en) | 2012-12-19 | 2015-10-28 | Adimab, LLC | Multivalent antibody analogs, and methods of their preparation and use |
| JP6359031B2 (ja) * | 2012-12-21 | 2018-07-18 | メディミューン，エルエルシー | 抗ｈ７ｃｒ抗体 |
| CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
| MX387324B (es) | 2013-01-10 | 2025-03-18 | Genmab Bv | Variantes de regiones fc de igg1 de humano y usos de las mismas. |
| US9701759B2 (en) * | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| HK1218930A1 (zh) | 2013-02-08 | 2017-03-17 | Abbvie Stemcentrx Llc | 新型多特异性结构 |
| US20160015749A1 (en) * | 2013-03-05 | 2016-01-21 | Baylor College Of Medicine | Engager cells for immunotherapy |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US10047167B2 (en) | 2013-03-15 | 2018-08-14 | Eli Lilly And Company | Methods for producing fabs and bi-specific antibodies |
| CA2904805A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| CA2913363A1 (en) | 2013-05-24 | 2014-11-27 | Zymeworks Inc. | Modular protein drug conjugate therapeutic |
| EP3004174B1 (en) | 2013-05-31 | 2019-04-17 | Zymeworks Inc. | Heteromultimers with reduced or silenced effector function |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| CA2925256C (en) | 2013-09-27 | 2023-08-15 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| BR112016006929A2 (pt) | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
| CN113248613B (zh) | 2014-01-15 | 2024-08-23 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN结合性质的Fc区变体 |
| CN110981957B (zh) | 2014-01-15 | 2024-12-24 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| CN110903398B (zh) | 2014-01-15 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
| EP3107565A4 (en) | 2014-02-21 | 2017-08-23 | Regeneron Pharmaceuticals, Inc. | Methods, compositions and kits for cell specific modulation of target antigens |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| JP6592505B2 (ja) * | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| DK3107938T3 (da) | 2014-05-28 | 2022-07-11 | Zymeworks Inc | Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf |
| WO2015197582A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| AU2015279321B2 (en) | 2014-06-27 | 2021-03-04 | Innate Pharma, S.A. | Multispecific antigen binding proteins |
| JP6822849B2 (ja) * | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| EP3174897B1 (en) | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| PL3177643T3 (pl) | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T |
| GB201414823D0 (en) | 2014-08-20 | 2014-10-01 | Argen X Bv | Multispecific antibodies |
| RU2713131C1 (ru) | 2014-11-06 | 2020-02-03 | Ф. Хоффманн-Ля Рош Аг | ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А |
| PT3215528T (pt) | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
| ES2808853T3 (es) | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| ES2935274T3 (es) | 2014-12-05 | 2023-03-03 | Merck Patent Gmbh | Anticuerpo con intercambio de dominios |
| WO2016115274A1 (en) | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| CN107922476A (zh) | 2015-03-13 | 2018-04-17 | 诺夫免疫股份有限公司 | 纯化双特异性抗体的方法 |
| JP6996979B2 (ja) * | 2015-03-31 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 三量体ｔｎｆファミリーリガンドを含む抗原結合分子 |
| JP7461620B2 (ja) * | 2015-10-06 | 2024-04-04 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 治療用化合物及び方法 |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
-
2017
- 2017-03-21 US US15/465,564 patent/US11291721B2/en active Active
- 2017-03-21 CN CN201780028089.4A patent/CN109153728A/zh active Pending
- 2017-03-21 WO PCT/US2017/023483 patent/WO2017165464A1/en not_active Ceased
- 2017-03-21 AU AU2017238172A patent/AU2017238172B2/en active Active
- 2017-03-21 CA CA3016563A patent/CA3016563A1/en active Pending
- 2017-03-21 JP JP2019500742A patent/JP7082604B2/ja active Active
- 2017-03-21 EP EP17718441.3A patent/EP3433281A1/en not_active Withdrawn
-
2022
- 2022-01-26 US US17/584,892 patent/US20220288200A1/en active Pending
- 2022-04-04 JP JP2022062657A patent/JP2022088627A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fenis et al. | New immune cell engagers for cancer immunotherapy | |
| JP7293456B2 (ja) | 誘導性結合タンパク質及びその使用方法 | |
| US20240327527A1 (en) | Activatable antibodies and methods of use thereof | |
| JP2026048631A (ja) | マスクされたｉｌ－１２サイトカイン及びその切断産物 | |
| JP6800141B2 (ja) | Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置 | |
| Kontermann | Recombinant bispecific antibodies for cancer therapy | |
| KR102629905B1 (ko) | 항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조 | |
| CN118546960A (zh) | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 | |
| CA3130508A1 (en) | Antibody molecules that bind to nkp30 and uses thereof | |
| BR112018007445A2 (pt) | anticorpos fv multivalentes | |
| US20230348593A1 (en) | Antibody molecules that bind to nkp30 and uses thereof | |
| JP2025500522A5 (enExample) | ||
| CN110088124A (zh) | 与免疫球蛋白重链恒定区异源二聚体(异源二聚体Fc)融合的Il-21(异源二聚体Fc融合IL-21)以及包含其的药物组合物 | |
| AU2004210088A1 (en) | Trimeric polypeptide construct to induce an enduring T cell response | |
| CN104203981A (zh) | 双特异性抗体分子 | |
| US20180028631A1 (en) | Anti-ssea4 chimeric antigen receptors and their use for treating cancer | |
| ES2717308T3 (es) | Células madre pluri- o multi-potentes genéticamente modificadas y sus usos | |
| CA3000597C (en) | Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition | |
| CA3090407A1 (en) | Fusion protein constructs comprising an anti-muc1 antibody and il-15 | |
| EP4031252A2 (en) | Multimeric antibodies with enhanced selectivity for cells with high target density | |
| Ahmed et al. | Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody | |
| WO2018140845A2 (en) | Bi-specific antibodies to cd64 and a disease antigen | |
| CN118019849A (zh) | Il-2变体及其融合蛋白 | |
| WO2016135239A1 (en) | Fusion protein comprising three binding domains to her2 | |
| US20230134345A1 (en) | Chimeric antigen receptor comprising third signal receptor and use thereof |